BioSpace News Archive

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a public offering price of $11.00 per share.

Kintor Pharmaceutical Limited is pleased to announce that the investigational new drug application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration of China.